Research on multiple sclerosis is revealing more about what we don't know, than what we do know about the disease. One popular hypothesis on how the disease starts has now been disproven .

Multiple Sclerosis (MS) damages the nervous systems of the brain and spinal cord. This leads to many symptoms, most notably cognitive decline. However a new rehab program may be able to help.

A multiple sclerosis drug may work double duty. It has been shown in a lab study to prevent and even reverse one of the leading causes of heart attack.

In some patients, multiple sclerosis attacks the body in such a way that leg muscles begin to deteriorate, and many patients end up with a cane or walker before they reach old age.

Tysabri , one of the few drugs approved to treat multiple sclerosis, is getting a label makeover courtesy of the FDA. The new look shows off a newly approved safety test for patients.

American and European health agencies are investigating the role of Gilenya , the first approved pill for treating multiple sclerosis.

Multiple sclerosis is notorious for doing damage to the brain's ability to communicate with the rest of the body. But what creates the decline in mental clarity that some patients experience?

Multiple sclerosis does its damage in a patient's brain, and that's where most drugs are targeted. But one drug holds the dangerous risk of a severe brain infection for some patients.

Multiple sclerosis is generally thought of as an adult's disease. But symptoms can strike as early as childhood, a condition known as pediatric multiple sclerosis.

One of multiple sclerosis' hallmarks are lesions in the brain. They're blamed for causing chronic and worsening disability. But a new finding suggests that's not the full picture.